CEO & Founder
Sid is a pharma and biotech leader and cell therapy innovator whose work helped establish MAGE-A as a pan-cancer immunotherapy target and advanced next-generation IL-12–engineered T cell therapies. He is now pioneering in vivo gene engineering approaches to treat and potentially prevent life-threatening allergies, anaphylaxis, mast cell–driven diseases, and select leukemias.
Boehringer-Ingelheim Pharmaceutical
Eli Lilly & Company
Exuma Biotech
Member of the Board of Directors
Gad is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm, focusing in the fields of mRNA-based therapeutics and genomic medicines. He brings over 35 years of experience in biotech business & corporate development, strategy, finance, and venture management. He completed a dozen strategic partnerships and licensing deals, and multiple financings for both private and public companies.
Research Associate
Alan is an experienced scientist and educator with expertise in experimental execution, data generation, and hands-on laboratory management.
Beckman Coulter
Immunity Bio
Exuma Biotech
Lead Advisor
Dr. Bochner is a physician–scientist and internationally recognized leader in Allergy, Asthma, and Immunology, best known for his pioneering work on mast cells, basophils and eosinophils, and inhibitory immune receptors
Lead Advisor
Dr. Muranski is a physician–scientist and internationally recognized leader for his contributions to T-cell biology and adoptive cell therapy, particularly in the context of cancer immunotherapy